Atomoxetine Treatment for Cognitive Impairment in Parkinson’s Disease (ATM-Cog)
Condition(s):Parkinson’s Disease; Cognitive ImpairmentLast Updated:August 23, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Parkinson’s Disease; Cognitive ImpairmentLast Updated:August 23, 2018Completed
Condition(s):Attention Deficit Hyperactivity DisorderLast Updated:January 20, 2011Completed
Condition(s):Physiological StressLast Updated:December 12, 2011Completed
Condition(s):Fetal Alcohol Syndrome; Attention Deficit Hyperactivity Disorder (ADHD)Last Updated:July 2, 2017Completed
Condition(s):Attention Deficit Hyperactivity DisorderLast Updated:March 28, 2016Completed
Condition(s):Alcohol Craving; Mood ChangesLast Updated:August 3, 2011Terminated
Condition(s):Attention Deficit Hyperactivity Disorder; DyslexiaLast Updated:December 15, 2011Completed
Condition(s):Attention Deficit Hyperactivity DisorderLast Updated:January 12, 2010Completed
Condition(s):Attention Deficit Hyperactivity DisorderLast Updated:January 17, 2011Completed
Condition(s):Attention Deficit Hyperactivity Disorder; DyslexiaLast Updated:February 20, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.